β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 41, 2012, Pages 16660-16665

  Nichols, Heddie L ^a   Saffeddine, Mahmoud ^b   Theriot, Barbara S ^b   Hegde, Akhil ^b   Polley, Daniel ^b   El Mays, Tamer ^c   Vliagoftis, Harissios ^d   Hollenberg, Morley D ^b   Wilson, Emma H ^a   Walker, Julia K L ^b   DeFea, Kathryn A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; BETA ARRESTIN 2; CALCIUM ION; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; MUCIN; OVALBUMIN; PROSTAGLANDIN E2; PROTEINASE ACTIVATED RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHODILATATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FLOW CYTOMETRY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RESPIRATORY TRACT INFLAMMATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; WILD TYPE;

ANIMALS; ARRESTINS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DINOPROSTONE; FLOW CYTOMETRY; INFLAMMATION; INTERLEUKIN-13; LEUKOCYTES; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; RECEPTOR, PAR-2;

EID: 84867342486     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1208881109     Document Type: Article

References (46)

1. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD (2012) Targeting proteinase-activated receptors: Therapeutic potential and challenges. Nat Rev Drug Discov 11:69-86.
2. Cocks TM, Moffatt JD (2001) Protease-activated receptor-2 (PAR2) in the airways. Pulm Pharmacol Ther 14:183-191. (Pubitemid 32619923)
3. Oikonomopoulou K, et al. (2006) Proteinase-mediated cell signalling: Targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol Chem 387:677-685. (Pubitemid 43964789)
4. Arizmendi NG, et al. (2011) Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. J Immunol 186:3164-3172.
5. Boitano S, et al. (2011) Potent agonists of the protease activated receptor 2 (PAR2). J Med Chem 54:1308-1313.
6. Hollenberg MD, et al. (2008) Derivatized 2-furoyl-LIGRLO-amide, a versatile and selective probe for proteinase-activated receptor 2: Binding and visualization. J Pharmacol Exp Ther 326:453-462.
7. McGuire JJ, Saifeddine M, Triggle CR, Sun K, Hollenberg MD (2004) 2-Furoyl-LIGRLO-amide: A potent and selective proteinase-activated receptor 2 agonist. J Pharmacol Exp Ther 309:1124-1131. (Pubitemid 38669700)
8. DeFea KA, et al. (2000) beta-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148:1267-1281.
9. Ge L, Ly Y, Hollenberg M, DeFea K (2003) A beta-arrestin-dependent scaffold is associated with prolonged MAPK activation in pseudopodia during protease-activated receptor-2-induced chemotaxis. J Biol Chem 278:34418-34426. (Pubitemid 37553288)
10. Wang P, DeFea KA (2006) Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 45:9374-9385. (Pubitemid 44223242)
11. Zoudilova M, et al. (2007) Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J Biol Chem 282:20634-20646. (Pubitemid 47100047)
12. Zoudilova M, et al. (2010) beta-Arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2. J Biol Chem 285:14318-14329.
13. Schmidlin F, et al. (2002) Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 169:5315-5321. (Pubitemid 35217205)
14. Takizawa T, et al. (2005) Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice. J Pharmacol Sci 98(1):99-102. (Pubitemid 40806134)
15. Ebeling C, et al. (2005) Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways. J Allergy Clin Immunol 115:623-630. (Pubitemid 40341720)
16. DeFea KA (2007) Stop that cell! Beta-arrestin-dependent chemotaxis: A tale of localized actin assembly and receptor desensitization. Annu Rev Physiol 69:535-560.
17. Cocks TM, et al. (1999) A protective role for protease-activated receptors in the airways. Nature 398:156-160.
18. Henry PJ (2006) The protease-activated receptor2 (PAR2)-prostaglandin E2-prostanoid EP receptor axis: A potential bronchoprotective unit in the respiratory tract? Eur J Pharmacol 533:156-170.
19. Kawao N, et al. (2005) Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. J Pharmacol Exp Ther 315:576-589. (Pubitemid 41500722)
20. Nagataki M, Moriyuki K, Sekiguchi F, Kawabata A (2008) Evidence that PAR2-triggered prostaglandin E2 (PGE2) formation involves the ERK-cytosolic phospholipase A2-COX-1-microsomal PGE synthase-1 cascade in human lung epithelial cells. Cell Biochem Funct 26:279-282. (Pubitemid 351373978)
21. Walker JKL, et al. (2003) β-Arrestin-2 regulates the development of allergic asthma. J Clin Invest 112:566-574. (Pubitemid 38056341)
22. Izuhara K, et al. (2009) The mechanism of mucus production in bronchial asthma. Curr Med Chem 16:2867-2875.
23. McGuire JJ, Hollenberg MD, Andrade-Gordon P, Triggle CR (2002) Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol 135:155-169. (Pubitemid 34102109)
24. Hollingsworth JW, et al. (2010) Both hematopoietic-derived and non-hematopoietic-derived beta-arrestin-2 regulates murine allergic airway disease. Am J Respir Cell Mol Biol 43:269-275.
25. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL (1999) Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol 127:1083-1090. (Pubitemid 29326629)
26. 2-adrenoceptor ligands in the treatment of asthma. Br J Pharmacol 163(1):18-28.
27. 2-adrenoceptors and exacerbates lung in flammation in mice. Br J Pharmacol 165:2365-2377.
28. Nguyen LP, et al. (2008) Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 38:256-262. (Pubitemid 351567693)
29. Nguyen LP, et al. (2009) Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci USA 106:2435-2440.
30. Callaerts-Vegh Z, et al. (2004) Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 101:4948-4953. (Pubitemid 38469183)
31. Mathurin K, et al. (2011) An interaction between L-prostaglandin D synthase and arrestin increases PGD2 production. J Biol Chem 286:2696-2706.
32. Kendall RT, et al. (2011) The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1,Ile4,Ile8]angiotensin II regulates a robust G proteinin-dependent signaling network. J Biol Chem 286:19880-19891.
33. Busse WW (2010) The relationship of airway hyperresponsiveness and airway inflammation: Airway hyperresponsiveness in asthma: Its measurement and clinical significance. Chest 138(2 Suppl):4S-10S.
34. Barrios VE, Jarosinski MA, Wright CD (2003) Proteinase-activated receptor-2 mediates hyperresponsiveness in isolated guinea pig bronchi. Biochem Pharmacol 66:519-525. (Pubitemid 36937038)
35. Knight DA, et al. (2001) Protease-activated receptors in human airways: Upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol 108:797-803. (Pubitemid 33096213)
36. Kanke T, et al. (2009) Novel antagonists for proteinase-activated receptor 2: Inhibition of cellular and vascular responses in vitro and in vivo. Br J Pharmacol 158(1):361-371.
37. De Campo BA, Henry PJ (2005) Stimulation of protease-activated receptor-2 inhibits airway eosinophilia, hyperresponsiveness and bronchoconstriction in a murine model of allergic inflammation. Br J Pharmacol 144:1100-1108. (Pubitemid 40593008)
38. D' Agostino B, et al. (2007) Activation of protease-activated receptor-2 reduces airways inflammation in experimental allergic asthma. Clin Exp Allergy 37:1436-1443. (Pubitemid 47460224)
39. 2, induces protease release from mast cells: Role in TNF degradation. BMC Pharmacol 4:12.
40. Ramachandran R, et al. (2009) Agonist-biased signaling via proteinase activated receptor-2: Differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol 76:791-801.
41. Ramachandran R, et al. (2011) Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J Biol Chem 286:24638-24648.
42. Sevigny LM, et al. (2011) Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci USA 108:8491-8496.
43. Remme WJ, et al. (2007) Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart Fail 9:1128-1135. (Pubitemid 350011059)
44. Wisler JW, et al. (2007) A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 104:16657-16662. (Pubitemid 350211072)
45. Schuessler TF, Bates JH (1995) A computer-controlled research ventilator for small animals: Design and evaluation. IEEE Trans Biomed Eng 42:860-866.
46. Proskocil BJ, Fryer AD (2005) Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2(4):305-310; discussion 311-312.